GLP-2 pen versus GATTEX
The GLP-2 Pen listing gives a 30mg amount, without identifying teduglutide or GATTEX. GATTEX is indicated in the United States for short-bowel syndrome in adults and children aged one year or older who depend on parenteral support. This is not a general intestinal-wellness indication, and it is not an indication established for the pen listed here. GATTEX prescribing information.
The label's medicine is teduglutide, a 33-amino-acid GLP-2 analogue. The catalogue identifies GLP-2 Pen and 30mg; it does not identify teduglutide, GATTEX or a particular peptide sequence. A presentation name and amount cannot substitute for the active-ingredient identity in the medicine label. GATTEX prescribing information.
GLP-2 and teduglutide
The GATTEX label describes teduglutide as an analogue of naturally occurring GLP-2, which is secreted by intestinal L-cells. This relationship explains why the GLP-2 term appears in the reference. It does not establish that an unsuffixed GLP-2 supplier name refers to the analogue used in the medicine. GATTEX prescribing information.
Three descriptions therefore remain separate: naturally occurring GLP-2, the named teduglutide analogue and the catalogue's GLP-2 Pen. The first provides biological context, the second identifies a labeled medicine ingredient, and the third identifies the supplier presentation. GATTEX prescribing information.
GATTEX safety warning
GATTEX carries a warning about acceleration of neoplastic growth. It is neither a finding about this pen's contents nor evidence that the supplier presentation is a GATTEX equivalent. GATTEX prescribing information.
For a presentation comparison, the separate GLP-2 vial is documented by its short name and photographed 30MG label. The pen's 30mg listing likewise remains a catalogue amount, rather than a concentration, a use instruction or proof of medicine equivalence.
GLP-2 pen and GATTEX questions
Can the GATTEX indication be applied to this pen?
Not from the GLP-2 name. The indication belongs to GATTEX and its named teduglutide ingredient, in the specified short-bowel-syndrome population dependent on parenteral support. GATTEX prescribing information.
